Quality use of medicines within universal health coverage: challenges and opportunities

BMC Health Services Research

Dennis Ross-Degnan²  Jonathan D Quick¹  Anita K Wagner² 

[1] Management Sciences for Health, 200 Rivers Edge Drive, Medford, MA 02155, USA;Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 133 Brookline Avenue, Boston, MA 02115, USA

关键词: Quality of care;    Health systems;    Financial incentives;    Pharmaceutical benefit;    Medicines;    Universal health coverage;   

Others  :  1126632
DOI  :  10.1186/1472-6963-14-357

 received in 2013-09-18, accepted in 2014-08-20,  发布年份 2014

【 摘 要 】

Background

Medicines are a major driver of quality, safety, equity, and cost of care in low and middle-income country health systems. Universal health coverage implementers must explicitly address appropriate use of medicines to realize the health benefits of medicines, avoid wasting scarce resources, and sustain the financial viability of universal health coverage schemes.

Discussion

Medicines are major contributors to the health and well-being of individuals and populations when used appropriately, and they waste resources and endanger health when used unnecessarily or incorrectly. Stakeholders need to balance inherently competing objectives in the pharmaceutical sector. Emerging and expanding UHC schemes provide potential levers to balance competing system objectives.

To use these levers, sustainable universal coverage programs will require a) information systems that can track medicines utilization, expenditures, and quality of medicines use; b) routine monitoring of indicators of medicines availability, access, affordability, and use; c) policies and programs that facilitate appropriate medicines use by prescribers, dispensers, and patients; d) transparency in setting priorities for medicines coverage under resource constraints; and e) a system perspective to engage diverse actors.

As they operationalize paths toward universal health coverage and include targeted medicines coverage policies and programs, systems can build on, and innovate, pharmaceutical policy frameworks and management tools from different countries’ settings.

Summary

Ensuring that medicines which achieve important health outcomes are available, accessible to all, used appropriately, and sustainably affordable is essential for realizing universal health coverage. Stakeholder cooperation and use of information and financing system levers provide opportunities to work toward this goal.

【 授权许可】

   
2014 Wagner et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Chan M: Remarks at the Launch of the World Health Report 2013: Research for Universal Health Coverage. Beijing; 2013. [Cited 10 September 2013]. Available from: http://www.who.int/dg/speeches/2013/whr_20130815/en/index.html webcite
• [2]IMS Institute for Healthcare Informatics: The global use of medicines. Outlook through 2017. [Cited 22 August 2014]. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Global_Use_of_Meds_Outlook_2017/IIHI_Global_Use_of_Meds_Report_2013.pdf webcite
• [3]Lu Y, Hernandez P, Abegunde D, Edejer T: The World Medicines Situation 2011: Medicine Expenditures. Geneva: World Health Organization; [Cited 22 August 2014]; Available from: http://apps.who.int/medicinedocs/documents/s18767en/s18767en.pdf webcite
• [4]World Health Report: Health Systems Financing: The Path to Universal Coverage. Geneva: World Health Organization; 2010. [Cited 01 April 2013]. Available from: http://www.who.int/whr/2010/en/index.html webcite
• [5]Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO: Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved. Value Health 2012, 15(5):664-673.
• [6]Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, Leowski J, Ewen M: The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007, 85(4):279-288. [Cited 22 August 2014]; Available from: http://www.who.int/bulletin/volumes/85/4/06-033647.pdf webcite
• [7]Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO: Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 2011, 89(6):412-421. [Cited 22 August 2014]; Available from: http://www.who.int/bulletin/volumes/89/6/10-084327.pdf webcite
• [8]Buckley GJ, Gostin LO: Countering the Problem of Falsified and Substandard Drugs. Washington: Institute of Medicine; 2013. [Cited 21 March 2013]. Available from: http://www.iom.edu/Reports/2013/Countering-the-Problem-of-Falsified-and-Substandard-Drugs.aspx webcite
• [9]World Health Organization: Medicines use in Primary Care in Developing and Transitional Countries. Fact Book Summarizing Results from Studies Reported Between 1990 and 2006. Geneva: World Health Organization; 2009. [Cited 01 April 2013]. Available from: http://apps.who.int/medicinedocs/documents/s16073e/s16073e.pdf webcite
• [10]Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK, Prospective Urban Rural Epidemiology (PURE) Study Innvestigators: Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011, 378(9798):1231-1242.
• [11]Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK: A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med 2011, 26(12):1479-1491.
• [12]Shahrawat R, Rao KD: Insured yet vulnerable: out-of-pocket payments and India’s poor. Health Policy Plan 2012, 27(3):213-221.
• [13]Yip W, Hsiao W: Non evidence-based policy: How effective is China’s new cooperative medical scheme in reducing medical impoverishment? Soc Sci Med 2009, 68(2):201-209.
• [14]UN Commission on Life-Saving Commodities for Women and Children: Commissioner’s report. 2012. [Cited 01 June 2013]. Available from: http://www.unicef.org/media/files/UN_Commission_Report_September_2012_Final.pdf webcite
• [15]Piette JD, Heisler M, Wagner TH: Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 2004, 27(2):3-391. doi:10.2337/diacare.27.2.384
• [16]Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner AK: Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence. Health Policy 2011, 100:134-143.
• [17]Carapinha J, Ross-Degnan D, Desta A, Wagner AK: Health insurance systems in five Sub-Saharan African countries: medicines benefits and data for decision making. Health Policy 2011, 99:193-202.
• [18]Backliwal A, Mani S: Navigating the new Thailand. 2011. [IMS Asia Pacific Insight 2011] 1:12-15. [Cited 22 August 2014]; Available from: http://www.imshealth.com/deployedfiles/ims/Global/Asia%20Pacific/2011_Magazine_Asia_softcopy%20FINAL.pdf webcite
• [19]World Health Organization: Global Health Observatory. [Cited 01 June 2013]. Available from: http://www.who.int/gho/en/ webcite
• [20]National Institute for Health and Care Excellence: Published clinical guidelines. [Cited 01 June 2013]. Available from: http://www.nice.org.uk/guidance/cg/published/index.jsp?p=off webcite
• [21]Various authors (BMJ Special Section): Moving forward on rationing. BMJ 2008, 337:903-906.
• [22]World Health Organization: Quality assurance and safety of medicines: Main challenges and strategic direction. [Cited 01 June 2013]. Available from: http://www.who.int/medicines/about/qsm_strategy/en/ webcite
• [23]Management Sciences for Health: MDS-3: Managing access to medicines and health technologies (MDS-3). Arlington, VA: Management Sciences for Health; 2012. [Cited 22 August 2014]. Available from: http://www.msh.org/resources/mds-3-managing-access-to-medicines-and-health-technologies webcite
• [24]Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H: Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev 2006, 19(2):CD005979.
• [25]Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, Kösters JP, Vernby A: Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev 2008, 23(1):CD007017.
• [26]Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, Kösters JP: Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev 2007, 18(3):CD006731.
• [27]Lu CY, Ross-Degnan D, Soumerai SB, Pearson S-A: Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature – 2001–2007. BMC Health Serv Res 2008, 8(1):75. BioMed Central Full Text
• [28]World Health Organization: Essential medicines [Cited 11 July 2013]. Available from: http://www.who.int/topics/essential_medicines/en/ webcite
• [29]Linley WG, Hughes DA: Societal views on NICE, cancer drugs fund, and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ 2013, 22:948-964.
• [30]Adam T, De Savigny D: Systems thinking for health systems strengthening in LMICs: seizing the opportunity. Health Policy Plann 2012, 27(Suppl 4):iv1-iv66.